Welcome to our dedicated page for Alphatec Hldgs SEC filings (Ticker: ATEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alphatec Holdings, Inc. filings document the reporting record of a spine-focused medical technology company. Its Form 8-K disclosures include quarterly and annual operating results, surgical and EOS revenue commentary, non-GAAP profitability measures, preliminary financial information and related press-release exhibits.
The company’s regulatory filings also cover material financing agreements, including senior secured credit facilities, revolving borrowing capacity, term-loan arrangements and references to convertible senior notes. Proxy and governance filings document director elections, board composition, executive and director compensation, equity awards, committee matters and other shareholder voting disclosures.
Alphatec Holdings, Inc. director Keith Valentine bought 135,000 shares of Common Stock in open-market transactions. The purchases occurred on May 7, 8, and 11, 2026 at weighted average prices around $7.00–$7.55 per share, increasing his direct holdings to 232,271 shares.
Footnotes explain that two of the trades were executed as multiple transactions within price ranges of $7.48–$7.50 and $7.52–$7.55 per share, with full trade-level details available on request.
Alphatec Holdings reported Q1 2026 revenue of $192.1 million, up 14% from $169.2 million a year earlier, driven by higher procedure volume and broader adoption of its spine surgery portfolio. Net loss narrowed to $33.9 million from $51.9 million as litigation expenses fell sharply.
Operating loss improved to $22.6 million versus $44.3 million, while interest expense increased due to the 0.75% Convertible Senior Notes due 2030. Cash and cash equivalents were $139.9 million and operating cash flow was modestly positive at $1.3 million.
Total debt included $405.0 million of 2030 convertible notes, $63.3 million of 2026 convertible notes, a $200.0 million Braidwell term loan and a $15.1 million revolving credit balance. After quarter-end, Alphatec replaced the Braidwell and MidCap facilities with a new $175.0 million term loan and $125.0 million revolver from JP Morgan maturing in 2031.
Alphatec Holdings reported Q1 2026 revenue of $192.1 million, up 14% from $169.2 million a year earlier, driven by higher procedure volume and broader adoption of its spine surgery portfolio. Net loss narrowed to $33.9 million from $51.9 million as litigation expenses fell sharply.
Operating loss improved to $22.6 million versus $44.3 million, while interest expense increased due to the 0.75% Convertible Senior Notes due 2030. Cash and cash equivalents were $139.9 million and operating cash flow was modestly positive at $1.3 million.
Total debt included $405.0 million of 2030 convertible notes, $63.3 million of 2026 convertible notes, a $200.0 million Braidwell term loan and a $15.1 million revolving credit balance. After quarter-end, Alphatec replaced the Braidwell and MidCap facilities with a new $175.0 million term loan and $125.0 million revolver from JP Morgan maturing in 2031.
Alphatec Holdings, Inc. reported strong first-quarter 2026 growth and refinanced its debt with an inaugural syndicated bank facility. The new $175 million Term Loan A and $125 million revolver, led by JPMorgan and TD Securities, replace prior term loan and ABL facilities and extend maturities to 2031. At closing, the facility bears interest at SOFR plus 275 basis points and is expected to cut annual interest expense by more than $6 million, with over $35 million of potential savings over its life.
For the quarter ended March 31, 2026, total revenue reached $192 million, up from $169.2 million, with surgical revenue of $178 million growing 17% year over year on 21% case volume growth. GAAP gross margin was 71% and non‑GAAP gross margin 72%. GAAP operating expenses were $159 million, yielding a GAAP net loss of $33.9 million, or $0.22 per share, while non‑GAAP net income was roughly breakeven at $0.4 million.
Non‑GAAP adjusted EBITDA rose to $20.7 million, an 11% margin and a 460‑basis‑point expansion year over year. The company ended the quarter with $140 million in cash and reaffirmed 2026 surgical revenue guidance of about $805 million, while trimming EOS revenue to $77 million. It now targets total 2026 revenue of approximately $882 million, 15% growth, adjusted EBITDA of about $134 million (15% margin), and at least $20 million of free cash flow.
Alphatec Holdings, Inc. reported strong first-quarter 2026 growth and refinanced its debt with an inaugural syndicated bank facility. The new $175 million Term Loan A and $125 million revolver, led by JPMorgan and TD Securities, replace prior term loan and ABL facilities and extend maturities to 2031. At closing, the facility bears interest at SOFR plus 275 basis points and is expected to cut annual interest expense by more than $6 million, with over $35 million of potential savings over its life.
For the quarter ended March 31, 2026, total revenue reached $192 million, up from $169.2 million, with surgical revenue of $178 million growing 17% year over year on 21% case volume growth. GAAP gross margin was 71% and non‑GAAP gross margin 72%. GAAP operating expenses were $159 million, yielding a GAAP net loss of $33.9 million, or $0.22 per share, while non‑GAAP net income was roughly breakeven at $0.4 million.
Non‑GAAP adjusted EBITDA rose to $20.7 million, an 11% margin and a 460‑basis‑point expansion year over year. The company ended the quarter with $140 million in cash and reaffirmed 2026 surgical revenue guidance of about $805 million, while trimming EOS revenue to $77 million. It now targets total 2026 revenue of approximately $882 million, 15% growth, adjusted EBITDA of about $134 million (15% margin), and at least $20 million of free cash flow.
Alphatec Holdings, Inc. is soliciting proxies for its 2026 Annual Meeting on June 10, 2026, where stockholders will elect seven directors, ratify Deloitte & Touche LLP, and vote on new 2026 equity incentive and employee stock purchase plans plus an advisory say‑on‑pay proposal.
The record date is April 15, 2026, with 153,702,057 common shares outstanding, each entitled to one vote without cumulative voting. The proxy describes board and committee structure, executive leadership, ownership of major holders, and a pay‑for‑performance program tied to revenue growth and equity‑based incentives.
Alphatec Holdings, Inc. General Counsel and Corporate Secretary Marshall Tyson Eliot exercised employee stock options for a total of 102,500 shares of common stock on April 7, 2026, at exercise prices ranging from $1.68 to $3.34 per share.
The options were exercised on a cashless basis. To cover the exercise prices, the issuer withheld 23,393 shares at $11.03 per share and issued 79,107 shares of common stock to the reporting person. Following these transactions, he directly owned 638,566 shares of Alphatec common stock.
Alphatec Holdings, Inc. Chief Financial Officer John Todd Koning reported an open-market sale of 79,789 shares of common stock on March 13, 2026 at a weighted average price of $12.36 per share, in transactions priced between $12.21 and $12.64.
After the sale, he directly holds 600,721 shares of Alphatec common stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025 to cover tax withholding obligations arising from the vesting of restricted stock units.
Alphatec Holdings, Inc. chief operating officer Scott Lish reported an open-market sale of 260,535 shares of common stock. The transaction took place on March 13, 2026 at a weighted average price of $12.30 per share, with individual trade prices ranging from $12.20 to $12.42. After this sale, Lish directly holds 815,704 shares of Alphatec common stock.
Alphatec Holdings, Inc. executive David Sponsel, EVP of Sales, sold 163,452 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $12.52 per share, with individual trade prices ranging from $12.13 to $12.92. After the sale, he directly holds 504,932 shares. According to the disclosure, these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted to cover tax withholding obligations from the vesting of restricted stock units.
ATEC representative filed a Form 144 proposing the sale of 79,789 restricted and performance stock units. The filing lists 79,789 securities tied to Restricted Stock Units & Performance Stock Units with dates noted as 02/01/2026 and a filing/date entry of 03/13/2026.
The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services and lists an amount $997,362.50 on the cover line; trading venue is shown as NASDAQ. The filing is a broker-dealer submission of a proposed resale under Form 144.